Summary
Regeneron Pharmaceuticals, Inc. reported strong financial results for the second quarter and first half of 2024, demonstrating robust revenue growth and increased profitability. Total revenues increased by 12% year-over-year for the second quarter to $3.55 billion and by 6% for the first half to $6.69 billion, driven by significant contributions from its key products, particularly Dupixent and EYLEA HD. Net product sales saw a healthy increase, with Dupixent sales up 27% in the second quarter and 26% in the first half. EYLEA HD and EYLEA combined U.S. net sales showed a slight increase of 2%, with EYLEA HD sales contributing $304.2 million in the quarter, reflecting strong patient adoption. Collaboration revenue also saw a substantial increase, primarily due to higher profit shares from Dupixent sales. The company's net income grew significantly, reaching $1.43 billion in the second quarter, a 48% increase year-over-year, resulting in diluted EPS of $12.41. For the first half, net income increased by 21% to $2.15 billion, with diluted EPS of $18.68. The company also continued its share repurchase program, repurchasing $601.4 million in the second quarter, underscoring a commitment to returning capital to shareholders.
Financial Highlights
46 data points| Revenue | $3.55B |
| R&D Expenses | $1.20B |
| SG&A Expenses | $758.80M |
| Operating Expenses | $2.48B |
| Operating Income | $1.07B |
| Net Income | $1.43B |
| EPS (Basic) | $13.25 |
| EPS (Diluted) | $12.41 |
| Shares Outstanding (Basic) | 108.10M |
| Shares Outstanding (Diluted) | 115.40M |
Key Highlights
- 1Total revenues increased by 12% to $3.55 billion in Q2 2024 and by 6% to $6.69 billion in H1 2024, driven by strong product sales and collaboration revenues.
- 2Net product sales for Dupixent increased by 27% in Q2 and 26% in H1, showcasing continued strong market performance.
- 3EYLEA HD and EYLEA combined U.S. net sales grew by 2% in H1 2024, with EYLEA HD contributing $304.2 million in Q2 as patient adoption continues.
- 4Net income surged by 48% to $1.43 billion in Q2 2024, resulting in diluted EPS of $12.41, up from $8.50 in the prior year period.
- 5Research and development expenses increased by 11% year-over-year for the quarter, indicating continued investment in pipeline advancement.
- 6The company actively managed its capital, repurchasing $601.4 million of common stock in Q2 2024, and had $3.631 billion remaining under its share repurchase programs as of June 30, 2024.
- 7The company's cash and cash equivalents decreased from $2.73 billion to $1.92 billion, while marketable securities increased significantly, indicating strategic deployment of capital.